Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Pharmaceutical Biotechnology

Volume 9 Issue 6
ISSN: 1389-2010
eISSN: 1873-4316

 

   All Titles

  Monoclonal Antibodies as Innovative Therapeutics
  pp.423-430 (8) Author: Janice M. Reichert
 
 
      Abstract

Monoclonal antibodies (mAbs) comprise the majority of protein candidates currently in clinical development because of their versatility as therapeutic agents. While traditionally associated with the biotechnology industry, mAb therapeutics are now being developed and marketed by most major pharmaceutical firms. A total of 21 products are approved in the US, with additional products marketed outside the US, and over 200 mAb candidates are currently undergoing clinical study. Benchmark data for mAb therapeutics, such as clinical development and US Food and Drug Administration approval times, approval success rates, and clinical phase transition probabilities, are critical for strategic planning purposes. Trends in these benchmarks for various types of mAbs, with an emphasis on those studied as anticancer and immunological therapeutics, are discussed.

 
  Keywords: Monoclonal antibodies, success rates, clinical study, Food and Drug Administration, marketing approval, benchmarks
  Affiliation: Tufts University, Tufts Center for the Study of Drug Development, 75 Kneeland Street, Suite 1100, Boston, MA 02111 USA.
 
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers
www.benthamscience.com

 

  Copyright © 1994 - 2014   Bentham Science Publishers